elironrasib | pharmaphorum

Skip to main content

Sunday 30 August 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

elironrasib

News

Pedestrian crossing green and red lights

MSD said to have pulled back from Revolution Meds deal

Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.

News

Spinning top in black and white, revolving

Report says MSD is in talks to buy Revolution Meds

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

Editor's Picks

Revolution's ASCO showstopper gets FDA greenlight

Anthropic AI tool conducts physical scientific experiments

UK MHRA authorises orforglipron private prescription

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321

Sword Health buys Headspace in $200m to $300m deal

News

Heart with clogged arteries

ESC26: Isomab safety evidence on blood vessel growth for CAD

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company